Article
Clinical Neurology
Marcos Gomez-Revuelta, Jose Maria Pelayo-Teran, Javier Vazquez-Bourgon, Victor Ortiz-Garcia de la Foz, Jacqueline Mayoral-van Son, Rosa Ayesa-Arriola, Benedicto Crespo-Facorro
Summary: This study compared the effectiveness of aripiprazole and risperidone in the acute-phase treatment of FEP and found no differences in treatment discontinuation rates and mean time until discontinuation between the two drugs. However, risperidone showed better performance in terms of clinical efficacy, but patients on risperidone were more likely to experience sex-related adverse events.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2021)
Article
Clinical Neurology
Lucia Garrido-Sanchez, Marcos Gomez-Revuelta, Victor Ortiz-Garcia De la Foz, Jose Maria Pelayo-Teran, Maria Juncal-Ruiz, Miguel Ruiz-Veguilla, Jacqueline Mayoral-Van Son, Rosa Ayesa-Arriola, Javier Vazquez-Bourgon, Benedicto Crespo-Facorro
Summary: This study compared the short-term effectiveness of aripiprazole and risperidone in patients with first episode psychosis (FEP). The results showed no statistically significant differences in treatment discontinuation rates and time to discontinuation between the two drugs. However, aripiprazole required higher dosage and extended time to achieve clinical response.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2022)
Article
Psychology, Developmental
Anne Katrine Pagsberg, Amanda Krogmann, Pia Jeppesen, Laura von Hardenberg, Dea G. Klauber, Karsten Gjessing Jensen, Ditte Ruda, Marie Stentebjerg Decara, Jens Richardt Mollegaard Jepsen, Birgitte Fagerlund, Anders Fink-Jensen, Christoph U. Correll, Britta Galling
Summary: The study evaluated the predictive factors for nonresponse in adolescents with first-episode psychosis, indicating that early nonresponse to antipsychotics reliably predicts long-term nonresponse and nonremission. PANSS-6 may be a clinically relevant alternative to PANSS-30 for predicting nonresponse at 12 weeks.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
(2022)
Review
Medicine, General & Internal
Bartosz Dawidowski, Adrianna Gorniak, Piotr Podwalski, Zofia Lebiecka, Blazej Misiak, Jerzy Samochowiec
Summary: Schizophrenia may be associated with immune dysfunction, with alterations in cytokine levels, childhood trauma, and disturbances in the gut microbiome potentially influencing its pathomechanism and clinical presentation. Different subtypes of schizophrenia, such as deficit schizophrenia, show variations in peripheral cytokine levels. The narrative review provides a comprehensive presentation of the evidence, utilizing a holistic approach to understand the complex relationships involved.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Psychiatry
L. A. Stabell, E. Johnsen, R. A. Kroken, E. M. Loberg, A. Blindheim, I. Joa, S. K. Reitan, M. Rettenbacher, P. Munk-Jorgensen, R. Gjestad
Summary: This study investigates the impact of antipsychotic treatment on clinical insight. It finds that antipsychotics, such as amisulpride and olanzapine, can improve insight over and above the reduction in total psychosis symptoms. However, the effect on insight compared to the effect of symptom reduction is still uncertain.
Article
Psychiatry
Renata Alisauskiene, Erik Johnsen, Rolf Gjestad, Rune A. Kroken, Eirik Kjelby, Igne Sinkeviciute, Farivar Fathian, Inge Joa, Solveig Klaebo Reitan, Maria Rettenbacher, Else-Marie Loberg
Summary: This study investigated the influence of drug use on the effectiveness of antipsychotic medication in patients with schizophrenia spectrum disorders (SSD). The results showed no significant differences in effectiveness among the three studied antipsychotics, regardless of drug use. However, older patients in the drug use group showed greater reduction in PANSS positive subscale score during treatment with amisulpride. Therefore, amisulpride may be a suitable choice for older patients with drug use.
GENERAL HOSPITAL PSYCHIATRY
(2023)
Article
Clinical Neurology
Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S. Bell Lynum, Sanjeda R. Chumki, Heather Fitzgerald, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Moeen Panni, Stephen R. Saklad
Summary: Aripiprazole 2-month ready-to-use 960 mg and Aripiprazole lauroxil 1064 mg are both long-acting injectable formulations used for the treatment of schizophrenia. Comparing the drug concentrations, both formulations maintain therapeutic levels over the 2-month dosing interval.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Article
Psychiatry
Nadia E. Crellin, Stefan Priebe, Nicola Morant, Glyn Lewis, Nick Freemantle, Sonia Johnson, Rob Horne, Vanessa Pinfold, Lyn Kent, Ruth Smith, Katherine Darton, Ruth E. Cooper, Maria Long, Jemima Thompson, Lisa Gruenwald, Robert Freudenthal, Jacki L. Stansfeld, Joanna Moncrieff
Summary: This study reveals that patients are commonly dissatisfied with the idea of taking antipsychotic medication on a long-term or life-long basis. The desire to reduce or stop medication is primarily motivated by adverse effects and health concerns. Patients value professional support in achieving reduction or discontinuation.
Article
Psychiatry
Fatima Hamieh, Souheil Hallit, Chadia Haddad, Sahar Obeid, Francois Kazour
Summary: This study aimed to classify patients with psychosis according to the McGorry staging model and compare factors between different stages. Data from 158 hospitalized patients with schizophrenia/psychosis were collected, and they were classified into three clinical stages: relapse, multiple relapses, and persistent and severe illness. Each stage was associated with well-defined clinical presentations, which can help determine appropriate treatment.
Article
Psychiatry
J. Mayoral-van Son, Marcos Gomez-Revuelta, Rosa Ayesa-Arriola, Javier Vazquez-Bourgon, Victor Ortiz-Garcia De La Foz, Miguel Ruiz-Veguilla, Nathalia Garrido, Diana Tordesillas-Gutierrez, Esther Setien-Suero, Benedicto Crespo-Facorro
Summary: The PAFIP 3 clinical trial aims to provide valuable information on clinical guidelines for treating patients with a first episode of non-affective psychosis and the benefits and risks of early use of clozapine in treatment-resistant patients.
REVISTA DE PSIQUIATRIA Y SALUD MENTAL
(2021)
Article
Neurosciences
Amir Englund, Dominic Oliver, Edward Chesney, Lucy Chester, Jack Wilson, Simina Sovi, Andrea De Micheli, John Hodsoll, Paolo Fusar-Poli, John Strang, Robin M. Murray, Tom P. Freeman, Philip McGuire
Summary: As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful effects of cannabis use. This study aimed to determine if increasing the CBD content of cannabis can reduce its harmful effects. The results showed that increasing the CBD content did not reduce the harmful effects of cannabis on memory and psychotic symptoms. Therefore, CBD may not protect against the acute adverse effects of cannabis.
NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Psychiatry
Elena G. Kornetova, Alexander N. Kornetov, Irina A. Mednova, Anastasia A. Goncharova, Valeria Gerasimova, Ivan Pozhidaev, Anastasiia S. Boiko, Arkadiy Semke, Anton J. M. Loonen, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: The study reveals significant variations in the prevalence of metabolic syndrome among patients with schizophrenia in different psychiatric hospitals within the same region, highlighting the importance of individualized approaches to minimize the risk of its occurrence based on the specific characteristics of each hospital.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Medicine, General & Internal
Alexander Hodkinson, Carl Heneghan, Kamal R. Mahtani, Evangelos Kontopantelis, Maria Panagioti
Summary: Risperidone and Paliperidone are treatments for schizophrenia or bipolar disorder. Meta-analysis shows that these antipsychotics have a small beneficial effect on reducing PANSS score over 9 weeks, which is more conservative than estimates based on journal publications. Clinical study reports contain significantly more data on harms that were unavailable in journal publications or trial registries.
Article
Psychiatry
Iris E. Sommer, Janna N. . de Boer
Summary: The aim of this article is to find accurate and valid markers for diagnosis, prognosis, and treatment monitoring in patients with schizophrenia-spectrum disorders. The authors explore the fields of computational linguistics and artificial intelligence, as automatic analysis of spoken language may provide useful markers for psychiatry. They intend to collaborate with language teams worldwide to advance this field and develop tools for self-monitoring by service users and assisting clinicians in diagnosis, treatment monitoring, and risk prediction.
PSYCHIATRY RESEARCH
(2022)
Article
Psychiatry
Thinh Nguyen, Jacqueline Frayne, Stuart Watson, Tamara Lebedevs, Stephanie Teoh, Megan Galbally
Summary: This study aimed to examine the outcomes of pregnancy, neonates, and psychosocial factors in women treated with long-acting injectable antipsychotics (LAI) at a tertiary maternity hospital. The findings showed that pregnant women treated with LAIs were more likely to experience pregnancy complications, such as gestational diabetes and hypertension, and had higher rates of psychiatric admissions and involvement with child protection services. The study highlights the need for enhanced multidisciplinary pregnancy care for this vulnerable population.
PSYCHIATRY RESEARCH
(2022)
Article
Psychology, Clinical
C. Lemvigh, R. Brouwer, R. Hilker, S. Anhoj, L. Baandrup, C. Pantelis, B. Glenthoj, B. Fagerlund
Summary: Background research has shown that both genetic and environmental factors contribute to the risk of schizophrenia. This study examined twin pairs discordant for schizophrenia to identify factors that differ between patients and their unaffected co-twins. The results suggested that childhood trauma, regular cannabis use, and a polygenic risk score for schizophrenia were independent predictors of vulnerability to schizophrenia. Additionally, regular cannabis use was found to be a predictor of having a schizophrenia spectrum diagnosis.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Anesthesiology
Sine Wichmann, Martin Schonemann-Lund, Anders Perner, Theis S. Itenov, Theis Lange, Christian Gluud, Rasmus E. Berthelsen, Anne C. Brochner, Jorgen Wiis, Morten H. Bestle
Summary: This study aimed to evaluate the effects of diuretics on fluid overload in ICU patients. The results showed that diuretics did not have a significant impact on the number of days alive and out of hospital at 90 days.
ACTA ANAESTHESIOLOGICA SCANDINAVICA
(2023)
Article
Psychiatry
Celso Arango, Andrea Fagiolini, Philip Gorwood, John M. Kane, Sergio Diaz-Mendoza, Navdeep Sahota, Christoph U. Correll
Summary: This study investigated the use of long-acting injectable antipsychotics (LAIs) in patients with first-episode psychosis (FEP) and early-phase (EP) schizophrenia. The expert consensus concluded that LAIs can decrease the risk of relapse, rehospitalization, and functional dysfunction, and highlighted the potential for multidimensional longer-term functional recovery beyond symptomatic remission.
Review
Psychiatry
Gonzalo Salazar de Pablo, Ana Catalan, Julio Vaquerizo Serrano, Borja Pedruzo, Luis Alameda, Veronica Sandroni, Alvaro Armendariz, Victoria Rodriguez, Celso Arango, Carmen Moreno, Johnny Downs, Chris Abbott, Jae Il Shin, Marco Solmi, Paolo Fusar-Poli, Christoph U. Correll
Summary: This study aims to provide a comprehensive review and meta-analysis of the diagnosis, prognosis, and treatment of negative symptoms in children and adolescents with early-onset psychosis (EOP) and those at clinical high risk for psychosis (CHR-P). The findings indicate that negative symptoms are common in children and adolescents at early stages of psychosis, particularly in those at CHR-P, and are associated with poor outcomes. Therefore, further intervention research is needed to provide evidence-based treatments.
BRITISH JOURNAL OF PSYCHIATRY
(2023)
Article
Environmental Sciences
Iben Have Beck, Niels Bilenberg, Helle Raun Andersen, Fabio Trecca, Dorthe Bleses, Tina Kold Jensen
Summary: This study investigated the association between prenatal and early postnatal PFAS exposure and delayed language development in Danish children aged 18 to 36 months, and found no significant association between PFAS exposure and language development. The study recommends assessing child serum PFAS at an older age, considering the potential positive effect of breastfeeding on neurodevelopment.
ENVIRONMENTAL HEALTH
(2023)
Article
Neurosciences
Fabian Huth, Leonardo Tozzi, Michael Marxen, Philipp Riedel, Kyra Broeckel, Julia Martini, Christina Berndt, Cathrin Sauer, Christoph Vogelbacher, Andreas Jansen, Tilo Kircher, Irina Falkenberg, Florian Thomas-Odenthal, Martin Lambert, Vivien Kraft, Gregor Leicht, Christoph Mulert, Andreas J. Fallgatter, Thomas Ethofer, Anne Rau, Karolina Leopold, Andreas Bechdolf, Andreas Reif, Silke Matura, Silvia Biere, Felix Bermpohl, Jana Fiebig, Thomas Stamm, Christoph U. Correll, Georg Juckel, Vera Flasbeck, Philipp Ritter, Michael Bauer, Andrea Pfennig, Pavol Mikolas
Summary: The pathophysiology of bipolar disorder (BD) is unclear, but a valid biomarker is needed for early detection. This study used structural MRI to compare volumes of hippocampus, amygdala, and their subfields/nuclei in individuals at risk for BD. Although there were no volume differences between risk groups, machine learning could still predict the risk for BD based on certain criteria. This suggests that neural changes may have prognostic value in BD.
Review
Psychiatry
Sabine Arnold, Christoph U. U. Correll, Charlotte Jaite
Summary: Youth with eating disorders, especially those who are inpatient, have a high risk of suicidal ideation and suicide attempts. This study found that almost half of the patients with anorexia nervosa binge-purging type (AN-BP) and bulimia nervosa (BN) had lifetime suicidal ideation, and approximately 10% of AN-BP patients had attempted suicide. Treatment programs should address the specific clinical correlates of suicidality, such as low body weight, psychiatric comorbidities, history of childhood abuse, and non-suicidal self-injury.
BORDERLINE PERSONALITY DISORDER AND EMOTION DYSREGULATION
(2023)
Article
Psychology, Clinical
Christina Horsager, Erica M. LaFata, Emil Faerk, Marlene Briciet Lauritsen, Soren Dinesen Ostergaard, Ashley N. Gearhardt
Summary: The aim of this study was to establish a categorical scoring option for the YFAS-C 2.0 and validate its psychometric properties in adolescents. The results showed that the full version of the YFAS-C 2.0 is a valid measure for assessing clinically significant food addiction in adolescents. The prevalence of food addiction was 5.0% in the general population and 11.2% in the population with a history of mental disorder.
EUROPEAN EATING DISORDERS REVIEW
(2023)
Article
Immunology
Julie B. Rosenberg, Jens Richardt Mollegaard Jepsen, Parisa Mohammadzadeh, Astrid Sevelsted, Rebecca Vinding, Mikkel E. Sorensen, David Horner, Kristina Aagaard, Birgitte Fagerlund, Susanne Brix, Nilofar Folsgaard, Ann -Marie M. Schoos, Jakob Stokholm, Bo Chawes, Christos Pantelis, Soren Dalsgaard, Birte Y. Glenthoj, Niels Bilenberg, Klaus Bonnelykke, Bjorn H. Ebdrup
Summary: Clinical data demonstrates a strong association between prenatal maternal inflammation assessed by hs-CRP and a diagnosis of ADHD by age 10. Maternal inflammation is also associated with ADHD symptom load in the entire cohort.
BRAIN BEHAVIOR AND IMMUNITY
(2024)
Article
Clinical Neurology
Martin Koster Rimvall, Ditte Vassard, Sabrina Mai Nielsen, Rasmus Trap Wolf, Kerstin Jessica Plessen, Niels Bilenberg, Per Hove Thomsen, Mikael Thastum, Simon-Peter Neumer, Louise Berg Puggaard, Mette Maria Agner Pedersen, Anne Katrine Pagsberg, Wendy K. Silverman, Christoph U. Correll, Robin Christensen, Pia Jeppesen
Summary: The study found that Mind My Mind (MMM) cognitive behavioral therapy is effective in treating common emotional and behavioral mental health problems in youth, but not all individuals respond satisfactorily to treatment. The analysis revealed that youths with any mental disorder at baseline, comorbidity, and longer duration of untreated mental health problems showed superior treatment benefits. This highlights the importance of community-based programs like MMM for youth with substantial mental health problems.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Peter J. Uhlhaas, Christopher G. Davey, Urvakhsh Meherwan Mehta, Jai Shah, John Torous, Nicholas B. Allen, Shelli Avenevoli, Tolulope Bella-Awusah, Andrew Chanen, Eric Y. H. Chen, Christoph U. Correll, Kim Q. Do, Helen L. Fisher, Sophia Frangou, Ian B. Hickie, Matcheri S. Keshavan, Kerstin Konrad, Francis S. Lee, Cindy H. Liu, Beatriz Luna, Patrick D. McGorry, Andreas Meyer-Lindenberg, Merete Nordentoft, Dost Oenguer, George C. Patton, Tomas Paus, Ulrich Reininghaus, Akira Sawa, Michael Schoenbaum, Gunter Schumann, Vinod H. Srihari, Ezra Susser, Swapna K. Verma, T. Wilson Woo, Lawrence H. Yang, Alison R. Yung, Stephen J. Wood
Summary: Most mental disorders have an onset between 12 and 25 years of age, emphasizing the importance of this period for understanding and addressing mental ill-health. This perspective highlights the interactions between risk and protective factors and brain development in the emergence of psychopathology in youth. It proposes the need for novel approaches to early diagnosis and interventions that reflect the evolving nature of psychopathology and promote knowledge exchange between science and practitioners. Overall, it advocates for a transformative early intervention paradigm to enhance mental health in young people and shift towards preventing severe mental disorders.
MOLECULAR PSYCHIATRY
(2023)
News Item
Clinical Neurology
Marco Solmi, Christoph U. Correll
Summary: Two recent studies analyze medication prescription, patient characteristics, and treatment effectiveness of people with schizophrenia using a French population-based disease registry. These studies also highlight the disparities in healthcare and outcomes for these individuals compared to the general population.
NATURE REVIEWS NEUROLOGY
(2023)
Meeting Abstract
Clinical Neurology
John Edwards, Suresh Durgam, Susan G. Kozauer, Jason Huo, Robert E. Davis, Sharon Mates, Christoph U. Correll
Letter
Psychiatry
John M. Kane, Taishiro Kishimoto, Eric Achtyes, Jose Rubio, Christoph Correll
